Benjamin Varco-Merth
Overview
Explore the profile of Benjamin Varco-Merth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varco-Merth B, Chaunzwa M, Duell D, Marenco A, Goodwin W, Dannay R, et al.
PLoS Pathog
. 2024 Aug;
20(8):e1012496.
PMID: 39173097
Persistence of the rebound-competent viral reservoir (RCVR) within the CD4+ T cell compartment of people living with HIV remains a major barrier to HIV cure. Here, we determined the effects...
2.
Keele B, Okoye A, Fennessey C, Varco-Merth B, Immonen T, Kose E, et al.
PLoS Pathog
. 2024 Apr;
20(4):e1012135.
PMID: 38593120
The rebound competent viral reservoir (RCVR)-virus that persists during antiretroviral treatment (ART) and can reignite systemic infection when treatment is stopped-is the primary barrier to eradicating HIV. We used time...
3.
Lavinder T, Fachko D, Stanton J, Varco-Merth B, Smedley J, Okoye A, et al.
Comp Med
. 2022 Sep;
72(5):287-297.
PMID: 36162961
HIV-infected people develop reproducible disruptions in their gastrointestinal microbiota. Despite the suppression of HIV viremia via long-term antiretroviral therapy (ART), alterations still occur in gut microbial diversity and the commensal...
4.
Haeseleer F, Fukazawa Y, Park H, Varco-Merth B, Rust B, Smedley J, et al.
Mol Ther Methods Clin Dev
. 2021 Sep;
22:304-319.
PMID: 34485613
Chimeric antigen receptor (CAR) T cell therapies are being investigated as potential HIV cures and designed to target HIV reservoirs. Monoclonal antibodies (mAbs) targeting the simian immunodeficiency virus (SIV) envelope...
5.
CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification
Okoye A, Duell D, Fukazawa Y, Varco-Merth B, Marenco A, Behrens H, et al.
J Clin Invest
. 2021 Feb;
131(8).
PMID: 33630764
To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion...
6.
Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber H, Hull P, et al.
J Virol
. 2021 Feb;
95(8).
PMID: 33536176
An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as...
7.
Varco-Merth B, Feigerlova E, Shinde U, Rosenfeld R, Hwa V, Rotwein P
Mol Endocrinol
. 2012 Nov;
27(1):150-61.
PMID: 23160480
The first genetic defect in human signal transducer and activator of transcription (STAT)5b was identified in an individual with profound short stature and GH insensitivity, immune dysfunction, and severe pulmonary...
8.
Lawrence R, Varco-Merth B, Bley C, Chen J, Fromme P
Protein Expr Purif
. 2010 Nov;
76(1):15-24.
PMID: 21040791
In chloroplasts, the multimeric ATP synthase produces the adenosine triphosphate (ATP) that is required for photosynthetic metabolism. The synthesis of ATP is mechanically coupled to the rotation of a ring...
9.
Varco-Merth B, Fromme R, Wang M, Fromme P
Biochim Biophys Acta
. 2008 Jun;
1777(7-8):605-12.
PMID: 18515064
The ATP synthase is one of the most important enzymes on earth as it couples the transmembrane electrochemical potential of protons to the synthesis of ATP from ADP and inorganic...